Refine Your Pitch Strategy, Sharpen Your Positioning to Investors, & Understand Expectations for Deal Conversations
Whether developing first-in-class degraders, best-in-class TCEs, novel payloads for ADCs, or AI-driven drug discovery platforms to validate new targets, the clinical and competitive challenges in today's landscape demand collaboration with pharma to validate technology, access capital, and leverage infrastructure to achieve Phase 3 success.
Bringing independent Autoimmunity, ADC, TPD, and TCE Partnering Summits into a single arena, the Oncology & Immunology Innovation Partnering & Licensing Summit gathers a critical mass of related discovery technologies and development pipelines.
Gain an Insight into:
- Which stage of development, in detail, are pharma and investors looking for?
- What data is valuable for pharma to see when not in the clinic?
- What is a key element of differentiation that a biotech can demonstrate?
- How much opportunity is there for novel targets?
- Which targets will be most important in 10 years’ time?
Through a dedicated one-to-one partnering system, organized matchmaking, and total audience alignment, pharma can efficiently meet, provide feedback on, and compare licensing and co-development opportunities, whilst biotech business development can cut through the noise and competition to secure guaranteed meetings with key stakeholders.
Attending Companies Include